Role of parecoxib sodium in the multimodal analgesia after total knee arthroplasty

Safety and efficacy of parecoxib sodium in the multimodal analgesia after total knee arthroplasty: a prospective randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800014872

Enrollment

Unknown

Registered

2018-02-12

Start date

2018-03-01

Completion date

Unknown

Last updated

2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis or rheumatoid arthritis

Interventions

Experimental group:Preoperative intravenous injection of parecoxib sodium and postoperative intravenous patient-controlled analgesia

Control group:Preoperative normal saline injection and postoperative intravenous patient-controlled analgesia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hospitalized patients over the age of 18 with intact cognitive function, no gender restriction; 2) Diagnosed as osteoarthritis (OA) or rheumatoid arthritis (RA) before operation, with unsatisfactory response to conservative treatment; 3) No obvious deformities and unilateral TKA was scheduled; 4) American Society of Anesthesiologists (ASA) = 2; 5) Post-stabilizing prosthesis was implanted; 6) An unified configuration of PCA pump was applied postoperatively.

Exclusion criteria

Exclusion criteria: 1) Allergic to parecoxib sodium, or any composite of the parecoxib sodium product. 2) History of severe allergic reaction, especially dermatological manifestations, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, or known history of allergic to sulfamides; 3) Active gastrointestinal bleeding or ulceration; 4) Allergic to NSAIDS (including COX-2 inhibitors); 5) Pregnancy or breast-feeding; 6) Severe liver dysfunction (serum albumin < 25 g/L, or Child-Pugh score = 10); 7) Inflammatory bowel disease; 8) Congestive heart failure [New York Heart Association (NYHA) II to IV]; 9) Ischemic cardiac diseases; 10) Disease of peripheral arteries or cerebral vessels; 11) Severe varus or valgus deformity and flexion deformity.

Design outcomes

Primary

Measure	Time frame
Visual analogue scale;	—

Secondary

Measure	Time frame
Morphine consumption of postoperative intravenous patient-controlled analgesia;Rescue analgesia consumption;Postoperative knee function;	—

Countries

China

Contacts

Public ContactXisheng Weng

Chinese Academy of Medical Sciences & Peking Union

Drwengxsh@163.com+86 13366200018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026